Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Dr Prem H Thurairajah

  • Senior Consultant, Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital
  • Senior Consultant, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation, National University Hospital
MBBS (India), MRCP (UK), PhD (UK)
Medicine, Organ Transplantation
Adult Liver Transplantation Programme, Gastroenterology & Hepatology
Special Interests:
​Viral Hepatitis, Hepatobiliary disease, Liver transplantation


Dr. Prem H Thurairajah graduated from Kasturba Medical College in India in 1997. He subsequently pursued training in Internal Medicine in the United Kingdom which culminated with membership to the Royal College of Physicians (MRCP) in 2002. He trained in Gastroenterology and Hepatology at the West Midlands Deanery, Birmingham, UK and completed two fellowship stints, his first in Transplant Hepatology at the Liver Unit at Queen Elizabeth Hospital in Birmingham and his second in Hepatobiliary endoscopy (ERCP and EUS) at the University College of London (UCL) before obtained his Completion of Certificate in Specialist Training (CCST) in 2011. He completed a period of research leading to a Doctorate in Philosophy (PhD) in the field of Hepatitis C in 2010. He is well published in peer reviewed journals and continues to engage in clinical research.

He worked as a Consultant Transplant Hepatologist at St. James University Hospital, Leeds, UK in 2012 before moving to the Liver Transplant Unit at the University of Kentucky, USA  as an Assistant Professor in Medicine where he served for 2 years. He moved to Singapore in 2014 and worked at Changi General Hospital , where he set up a treatment programme for Chronic Hepatitis C and served as the Director of Hepatology.


  • ​Philip Haige Award, Best Presentation for Viral Hepatitis , British Association of the Study of Liver (BASL - 2008)

Journals & Publications

  1. ​Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Wong YJ, Thurairajah PH, Kumar R, Tan J, Fock KM, Law NM, Li W, Kwek A, Tan YB, Koh J, Lee ZC, Kumar LS, Teo EK, Ang TL.J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15324. Online ahead of print.PMID: 33217040
  2. What is required for achieving hepatitis C virus elimination in Singapore? A modelling study. Chaillon A, Thurairajah PH, Hsiang JC, Martin NK.J Gastroenterol Hepatol. 2020 Aug 10. doi: 10.1111/jgh.15211. Online ahead of print.PMID: 32777859
  3. Point-of-care hepatitis C screening with direct access referral to improve linkage of care among people with substance misuse: a pilot randomised study. Hsiang JC, Sinnaswami P, Lee MY, Zhang MM, Quek KE, Tan KH, Wong YM, Thurairajah PH.Singapore Med J. 2020 Jul 30. doi: 10.11622/smedj.2020116. Online ahead of print.PMID: 32729280
  4. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. Wong YJ, Cheen MH, Hsiang JC, Kumar R, Tan J, Teo EK, Thurairajah PH. JGH Open. 2019 Feb 8;3(3):210-216
  5. Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. Thurairajah PH, Carbone M, Bridgestock H, Thomas P, Hebbar S, Gunson BK, Shah T, Neuberger J. Transplantation 2013 Apr 15;95(7):955-9
  6. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared with Liver Disease of Other Etiologies Worldwide. Shah ND, Ventura-Cots M, Abraldes JG et. al. Clin Gastroenterol Hepatol. 2019 Oct;17(11):2320-2329
  7. Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. Zhao Y, Thurairajah PH, Kumar R, Tan J, Teo EK, Hsiang JC. Hepatobiliary Pancreat Dis Int. 2019 Apr;18(2):143-148.
  8. Ombitasvir/paritaprevir/ritonavir+daclatasvir and ribavirin  associated drug induced liver injury and syndrome of inappropriate secretion of antiduretic syndrome: A case report Kumar R, Hsiang JC, Tan J, Thurairajah PH. Clin Mol Hepatol. 2019 Sep;25(3):326-330.
  9. VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature. Wong YJ, Chew SY, Hsiang JC, Thurairajah PH, Kumar R, Teo EK, Gokhale RS, Noor IBM, Tan J. Clin Mol Hepatol. 2019 Jun;25(2):218-222.
  10. TC-325 versus the conventional combinational combined technique for endoscopic treatment for endosocpic treatment of peptic ulcers with high-risk bleeding stigmata: A randomized pilot study. Kwek BEA, Ang TL, Ong PLJ, Tan YLJ, Ang SWD, Law NM, Thurairajah PH, Fock KM. J Dig Dis. 2017 Jun;18(6):323-329. 

Professional Memberships

  • ​European Association of Study of Liver
  • Singapore Medical Council


Back to Top